ArticleBMC urology2026
Added value of PHI in predicting lymph node invasion in prostate cancer: an external validation.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the predictive performance of the Briganti 2017 and MSKCC nomograms with the addition of Prostate Health Index (PHI) in a Chinese cohort of prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection.
methodsThis single-center retrospective study included 473 prostate cancer patients who underwent robot-assisted radical prostatectomy with extended pelvic lymph node dissection from Dec. 2021 to Dec. 2025. The two nomograms were validated, and PHI was incorporated as a continuous variable. Model performance was assessed using AUC, calibration plots, and decision curve analysis, with the DeLong test for AUC comparison. This study was registered in the Medical Research Registration and Filing Information System of the National Health Security Information Platform of China (Registration No.: MR-50-25-036796, retrospectively registered).
resultsLymph node invasion (pN1) was confirmed in 26.0% (123/473) of the cohort. The original Briganti 2017 and MSKCC nomograms had AUCs of 0.69 (95% CI: 0.61-0.79) and 0.71 (95% CI: 0.62-0.78) with satisfactory calibration. PHI incorporation significantly improved discrimination, raising their AUCs to 0.787 (absolute improvement 0.093, P < 0.01) and 0.782 (absolute improvement 0.077, P < 0.01), respectively. Decision curve analysis showed PHI expanded the threshold probability range of positive net benefit from 10% to 30% to 10%-40% for both models.
conclusionThe Briganti 2017 and MSKCC nomograms showed acceptable predictive performance for lymph node invasion in Chinese prostate cancer patients. PHI enhances their discriminatory ability and clinical utility, supporting its use as a valuable preoperative biomarker for pN1 in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.